Obalon Enters into a Distribution Agreement for Qatar
December 18 2019 - 8:30AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
weight loss solutions company with the first and only FDA-approved
swallowable, gas-filled intragastric balloon system for the
treatment of obesity, announces that it has entered into a
one-year agreement with Al Danah Medical Company (“Al Danah”) for
distribution of the Obalon Navigation Balloon System in
Qatar. Obalon has terminated its agreement with Bader Sultan
and Bros. Company for distribution of its prior-generation
balloons, which was set to expire on December 31, 2019.Obalon’s
President and CEO, Bill Plovanic commented, “While our primary
focus is on the development and operation of Company-owned retail
treatment centers in the U.S., we recognize that obesity remains a
global epidemic. We believe the agreement with Al Danah makes
clinical and economic sense and allows us to take a small step
forward internationally, without distracting us from our primary
commercial strategy in the United States.”
About Obalon
Therapeutics, Inc. Obalon Therapeutics, Inc.
(NASDAQ:OBLN) is a San Diego-based company focused on developing
and commercializing novel technologies for weight loss. For more
information, please visit http://www.obalon.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements that are
not purely historical regarding Obalon’s or its management’s
intentions, beliefs, expectations and strategies for the future,
including those related to new products and their potential
benefits. All forward-looking statements and reasons why results
might differ included in this press release are made as of the date
of this release, based on information currently available to
Obalon, deal with future events, are subject to various risks and
uncertainties, and actual results could differ materially from
those anticipated in those forward looking statements. The risks
and uncertainties that may cause actual results to differ
materially from Obalon’s current expectations are more fully
described in Obalon’s annual report on Form 10-K for the period
ended December 31, 2018, its quarterly report on Form 10-Q for the
period ended September 30, 2019 and its other reports, each as
filed with the Securities and Exchange Commission. Except as
required by law, Obalon assumes no obligation to update any such
forward-looking statement after the date of this report or to
conform these forward-looking statements to actual results.
For Obalon Therapeutics, Inc.
Investor Contact: Bill Plovanic President and Chief
Executive Officer Obalon Therapeutics, Inc. Office: +1
760 607 5103 wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2024 to May 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From May 2023 to May 2024